Skip to content

US · ENTX · BIOTECHNOLOGY

Entera Bio Ltd. (ENTX) intrinsic value and stock valuation

$3.31as of 2026-11-21 · Mkt cap 141.46M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Entera Bio Ltd. DCF and intrinsic value

InvestorsCraft values ENTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ENTX’s statements →

Entera Bio Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Jerusalem, JM 9112002 enterabio.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$40K-35.6% 5y CAGRd
20152025
Net income
-$-11.44M
20152025
Free cash flow
-$-7.48M
20152025
Total equity
$13.1M+11.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$40K$180K$0.00$130K$570K
Operating income-$-11.53M-$-9.59M-$-8.94M-$-13.07M-$-12.22M
Net income-$-11.44M-$-9.54M-$-8.89M-$-13.07M-$-12.19M
EPSd-$-247.67K-$-253.39K-$-306.45K-$-453.66K-$-466.51K
Operating cash flow-$-7.37M-$-6.82M-$-7.31M-$-12.5M-$-9.06M
Capital expenditure-$-110K-$0.00-$-20K-$-50K-$-20K
Free cash flow-$-7.48M-$-6.82M-$-7.33M-$-12.55M-$-9.08M
Total assets$16M$9.39M$11.8M$13.1M$26M
Total debt$490K$270K$390K$90K$300K
Net debt-$-6.62M-$-8.39M-$-10.63M-$-12.22M-$-24.59M
Total equity$13.1M$8.08M$10.4M$11.8M$22.6M
Cash and short-term investments$7.11M$8.66M$11M$12.3M$24.9M
Income statement
20252024202320222021
Revenue$40K$180K$0.00$130K$570K
Cost of revenue$40K$170K$60K$170K$370K
Gross profit$0.00$10K-$-60K-$-30K$200K
Research and development expenses$6M$4.5M$4.45M$5.78M$6.77M
Selling, general and administrative expenses$5.53M$5.09M$4.43M$7.25M$5.69M
Other expenses$0.00$0.00$0.00$0.00-$-50K
Operating expenses$11.5M$9.59M$8.88M$13M$12.4M
Cost and expenses$11.6M$9.77M$8.94M$13.2M$12.8M
Interest income$0.00$60K$30K$80K$0.00
Interest expense$0.00$0.00$0.00$0.00$30K
Depreciation and amortization$30K$50K$60K$60K$50K
Ebitda-$-11.41M-$-9.48M-$-8.8M-$-12.87M-$-12.16M
Operating income-$-11.53M-$-9.59M-$-8.94M-$-13.07M-$-12.22M
Total other income/expenses, net$90K$60K$80K$130K-$-30K
Income before tax-$-11.44M-$-9.53M-$-8.86M-$-12.93M-$-12.25M
Income tax expense$0.00$10K$30K$140K-$-60K
Net income-$-11.44M-$-9.54M-$-8.89M-$-13.07M-$-12.19M
Weighted average shares outstanding$46.2M$37.7M$29M$28.8M$26.1M
Weighted average diluted shares outstanding$46.2M$37.7M$29M$28.8M$26.1M
Balance sheet
20252024202320222021
Cash and short-term investments$7.11M$8.66M$11M$12.3M$24.9M
Net receivables$220K$130K$0.00$250K$180K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$7.11M$8.97M$11.3M$12.9M$25.3M
Property, plant and equipment, net$130K$330K$490K$230K$400K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$90K$80K$0.00$0.00$0.00
Total non-current assets$130K$420K$510K$280K$660K
Total assets$16M$9.39M$11.8M$13.1M$26M
Accounts payable$450K$130K$80K$20K$170K
Short-term debt$230K$170K$130K$90K$180K
Deferred revenue$0.00$0.00$0.00$0.00$10K
Total current liabilities$2.2M$1.18M$1.09M$1.34M$3.16M
Long-term debt$260K$100K$260K$0.00$120K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$690K$130K$290K$30K$260K
Capital lease obligations$230K$270K$390K$90K$300K
Total liabilities$2.89M$1.31M$1.38M$1.37M$3.42M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-125.37M-$-113.93M-$-104.39M-$-95.5M-$-82.43M
Accumulated other comprehensive income (loss)$40K$40K$40K$40K$40K
Total equity$13.1M$8.08M$10.4M$11.8M$22.6M
Total investments$90K$80K$0.00$0.00$0.00
Total debt$490K$270K$390K$90K$300K
Net debt-$-6.62M-$-8.39M-$-10.63M-$-12.22M-$-24.59M
Cash flow statement
20252024202320222021
Net income-$-11.44M-$-9.54M-$-8.89M-$-13.07M-$-12.19M
Depreciation and amortization$30K$50K$60K$60K$50K
Stock-based compensation$2.75M$2.56M$1.69M$2.25M$1.86M
Change in working capital$1.26M$110K-$-200K-$-1.83M$1.41M
Accounts receivable$130K-$-130K$250K-$-60K$70K
Inventory$0.00$0.00$0.00$0.00-$-70K
Accounts payable$320K$50K$70K-$-150K$70K
Net cash provided by operating activities-$-7.37M-$-6.82M-$-7.31M-$-12.5M-$-9.06M
Investments in property, plant and equipment-$-110K-$0.00-$-20K-$-50K-$-20K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-110K-$0.00-$-20K-$-100K-$-20K
Common stock issued$13.7M$3.96M$6.62M$10K$21.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.7M$4.48M$6.04M$10K$25.4M
Net change in cash$6.23M-$-2.35M-$-1.29M-$-12.58M$16.3M
Cash at end of period$15M$8.74M$11.1M$12.3M$25M
Operating cash flow-$-7.37M-$-6.82M-$-7.31M-$-12.5M-$-9.06M
Capital expenditure-$-110K-$0.00-$-20K-$-50K-$-20K
Free cash flow-$-7.48M-$-6.82M-$-7.33M-$-12.55M-$-9.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Entera Bio Ltd.

        Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

        CEO
        Miranda J. Toledano
        Employees
        21
        Beta
        1.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Entera Bio Ltd. (ENTX)?

        Entera Bio Ltd. (ENTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ENTX undervalued?

        ENTX trades at a price of $3.31 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.